Amal Therapeutics is a technology company.
Amal Therapeutics has raised $46.0M across 3 funding rounds.
Amal Therapeutics has raised $46.0M in total across 3 funding rounds.
Amal Therapeutics has raised $46.0M in total across 3 funding rounds.
Amal Therapeutics's investors include Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds.
Amal Therapeutics has raised $46.0M across 3 funding rounds. Most recently, it raised $33.0M Series B in November 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2018 | $33.0M Series B | Boehringer Ingelheim Venture Fund | |
| Sep 1, 2017 | $10.0M Series B | Boehringer Ingelheim Venture Fund | |
| Mar 1, 2016 | $3.0M Series A | Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds |
Amal Therapeutics is a Swiss biotechnology company specializing in the development of therapeutic cancer vaccines. It leverages its proprietary KISIMA® immunisation technology platform, which uniquely combines multiple elements into a single chimeric fusion protein to stimulate a potent and durable immune response against cancer. The company’s lead product, ATP128, targets metastatic colorectal cancer, aiming to improve treatment outcomes by enhancing the patient's immune system to create lasting immunological memory. Amal Therapeutics serves cancer patients and pharmaceutical partners focused on immuno-oncology, addressing the critical challenge of effective anti-cancer therapy. Since its acquisition by Boehringer Ingelheim in 2019, Amal has been advancing clinical trials and expanding its pipeline, demonstrating significant growth momentum in the cancer immunotherapy space[1][2][4].
Founded in 2012 in Geneva, Switzerland, Amal Therapeutics was established by a team of experts in immunology and oncology who sought to overcome the limitations of existing cancer treatments by harnessing the immune system. The idea emerged from the need for more effective therapeutic vaccines that could generate a robust and lasting immune response against tumors. Early traction was marked by the development of the KISIMA® platform and the initiation of clinical trials for ATP128, which positioned Amal as a pioneer in peptide-based cancer vaccines. The company’s evolution culminated in its acquisition by Boehringer Ingelheim, reflecting its promising technology and clinical progress[3][1][2].
Amal Therapeutics operates at the intersection of biotechnology and immuno-oncology, riding the global trend toward personalized cancer therapies and immune system modulation. The timing is critical as cancer immunotherapy has become a dominant focus in oncology, with increasing recognition of the immune system’s role in controlling tumors. Market forces such as rising cancer incidence, demand for more effective treatments, and advances in molecular biology favor the adoption of therapeutic vaccines. Amal’s technology contributes to the broader ecosystem by offering a novel platform that could complement or enhance existing immunotherapies like checkpoint inhibitors, potentially expanding treatment options and improving patient survival[1][2][3].
Looking ahead, Amal Therapeutics is poised to advance its clinical programs, particularly ATP128, through pivotal trials that could validate its therapeutic vaccine approach. Trends shaping its journey include the growing integration of multi-antigen vaccines, combination therapies with checkpoint inhibitors, and precision oncology targeting specific mutations like KRAS. As the company leverages Boehringer Ingelheim’s global infrastructure, its influence may expand beyond colorectal cancer to other hard-to-treat malignancies. Amal’s success could redefine cancer vaccine development, making immunotherapy more accessible and effective, thus fulfilling its mission to transform cancer patient outcomes[2][4].